Document Classification

Section Type: RESULTS

Text: In 16 patients who completed an extended open-label phase, fosinopril was associted with a decrease in protein excretion from 4. 53 to 3. 22 g/d, a reduction of 1. 29 g/d (CI, -2. 54 to -0. 05 g/d), which was associated with a reduction in serum total cholesterol (from 6. 37 to 5. 54 mmol/L, a decrease of 0. 84 mmol/L [CI, -1. 59 to -0. 08 mmol/L]), LDL cholesterol (from 4. 38 to 3. 72 mmol/L [a decrease of 0. 68 mmol/L [CI, -1. 33 to -0. 03 mmol/L]), and plasma lipoprotein (a) protein (from 3. 58 to 2. 81 mg/dL, a reduction of 0. 82 mg/dL [CI, -1. 58 to -0. 05 mg/dL]).